Gene therapy for alpha-1 antitrypsin deficiency.

Area of Science:

• Genetics and Molecular Biology
• Pulmonology
• Hepatology

Background:

• Alpha-1 antitrypsin (AAT) deficiency is a prevalent genetic disorder, particularly in individuals of Northern European descent.
• Severe AAT deficiency is linked to lung diseases like emphysema and liver disease due to AAT's role in neutralizing proteases and protein polymerization.
• The Z-AAT mutation impairs protein folding, leading to intracellular accumulation and potential liver damage.

Purpose of the Study:

• To review gene therapy strategies for Alpha-1 antitrypsin deficiency.
• To highlight recent advancements in clinical trials for both lung and liver manifestations of AAT deficiency.

Main Methods:

• Review of existing literature and clinical trial data on gene therapy for AAT deficiency.
• Analysis of therapeutic approaches targeting AAT augmentation and Z-AAT protein reduction.

Main Results:

• Gene therapy for AAT-deficient lung disease focuses on protein replacement strategies.
• Gene therapy for AAT-deficient liver disease requires downregulating Z-AAT protein production.
• Several gene therapy modalities have progressed to clinical trials.

Conclusions:

• Gene therapy offers distinct approaches for the lung and liver manifestations of AAT deficiency.
• Ongoing clinical trials are evaluating the efficacy and safety of novel gene therapies.
• Further research is crucial for developing effective treatments for AAT deficiency.